Frontage's Chris Ryan shares experiences and stories, as well as suggestions for how to set up a successful IND approach. We hope you will find our discussion insightful and help you avoid unexpected surprises in your IND-directed studies.
Chris Ryan is Senior Director of Business Development with Frontage Laboratories, Inc. supporting non-clinical safety and toxicology and drug metabolism and pharmacokinetics (’DMPK’) for pharma and biotech clients’ drug development programs. Mr. Ryan has worked for several Contract Research Organizations in drug development for over 18 years. As a former project manager for IND-directed programs, he has helped dozens of companies work through the complexities of pre-clinical safety and toxicology programs.
Register to gain access to gated resources.
Thank you for registering!
You may now view the resource below.
Performing robust exploratory tests upfront can save time and money later on in the process. This infographic outlines the top reasons for why clients are encouraged to consider a comprehensive exploratory toxicology program and how it can provide success in GLP studies.
In this paper, we provide practical advice on how to usher a small molecule through preliminary toxicology testing and derive information required to design IND-enabling studies. Indeed, with a rigorous exploratory toxicity program, sponsors can mitigate the risk of unexpected challenges and optimize the Good Laboratory Practice (GLP) study plan.
Frontage offers an impressive suite of services to take lead candidate drugs to the IND stage. With Experimur’s acquisition, Frontage now has significantly expanded our range of services, supporting customers’ drug-development programs beyond IND and into NDA-enabling toxicology studies. Frontage has exceptional bioanalytical supporting capabilities for small molecules, large molecules, and biomarkers.